Monday, December 23, 2024

Ibex and PathPresenter Launch Partnership to Accelerate Adoption of AI-powered Digital Pathology

Related stories

Doc.com Expands AI developments to Revolutionize Healthcare Access

Doc.com, a pioneering healthcare technology company, proudly announces the development...

Amesite Announces AI-Powered NurseMagic™ Growth in Marketing Reach to Key Markets

Amesite Inc., creator of the AI-powered NurseMagic™ app, announces...

Quantiphi Joins AWS Generative AI Partner Innovation Alliance

Quantiphi, an AI-first digital engineering company, has been named...
spot_imgspot_img

Ibex Medical Analytics, the leader in AI-powered cancer diagnostics, and PathPresenter, the global image sharing platform for pathology, announced a partnership to advance the adoption of AI-powered digital pathology. The two companies will work together to support joint customers via an AI-powered digital pathology solution for laboratories, hospitals and health systems worldwide.

“The digital pathology and AI transformation that Ibex and PathPresenter are championing is modernizing the industry and providing pathologists with AI tools to improve diagnostic accuracy, lab efficiencies and patient outcomes,” said Joseph Mossel, CEO and Co-Founder of Ibex Medical Analytics. “This partnership allows us to expand access to Galen™, Ibex’s AI platform, to PathPresenter’s impressive community of medical institutions around the world.”

PathPresenter is a secure and scalable multi-tenant enterprise workflow platform that has been developed by pathologists with deep domain knowledge and experience. Trusted by over 45 tier-one institutions, PathPresenter is the most comprehensive suite available for clinical care, remote consultations, education, and research. The solution provides expert guidance in storage optimization, tight integration with LIS systems through a proprietary HL7 engine, and robust incorporation of 3rd party and in-house-built AI algorithms.

Also Read: Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050

“We are committed to working with the best partners to advance digital pathology adoption and education, and Ibex is      a clear leader in AI-powered diagnostics,” said Dr. Rajendra Singh, founder of PathPresenter. “PathPresenter is building the much-needed ‘roads and bridges’ to connect the world’s pathologists, institutions, and pharma companies to easily share image data, AI algorithms, and domain expertise. Our deep knowledge of the digital pathology workflows is complemented well by Ibex’s clinically validated AI tools, enabling pathologists to benefit from a holistic diagnostic experience.”

Ibex‘s Galen platform is the most widely deployed AI technology in pathology and has been deployed in laboratories and pathology departments around the world. Galen supports clinicians worldwide with augmented capabilities during diagnosis of breast, prostate, and gastric biopsies. Improving diagnostic accuracy, reducing turnaround time, optimizing lab workflows and improving user experience for pathologists, Galen has demonstrated excellent outcomes across multiple clinical studies performed in different pathology labs and diagnostic workflows.

SOURCE: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img